• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      Dr Reddy's plans to launch Lipitor's generic version in US

      Posted AtBusiness-Standard.com

      Drug maker Dr Reddy’s Laboratories plans to launch generic version of the world’s largest selling anti-cholesterol medicine ‘Lipitor’ in the US market in the next 2-3 years.

      Lipitor, an anti- cholesterol drug from pharma major Pfizer Inc’s portfolio, has an annual market sales of over $12 billion (over Rs 56,000 crore).

      “We have filed an application for approval from the US Food and Drug Administration's for atorvastatin (the chemical name of Lipitor). Once we get the approval, we would launch it in the US market,” the Hyderabad-based Dr Reddy’s Laboratories COO Satish Reddy told reporters here.

      According to company officials, the application is not a Para IV filing. Under the new drug application submitted to the US drug regulator's approval, Para IV filing are those which seeks nod for launching the drug before expiry of patent.

      Indian pharma major Ranbaxy has resolved a patent dispute with Pfizer and has planned to launch the same drug in the US market in November 2011 with an 180-day exclusive period.

      Though, Dr Reddy’s Lab would not get the exclusivity for Lipitor but the company is hopeful about its sales in the US, the world’s largest drug market.

      “There are still opportunities in Lipitor,” Reddy said.

      According to industry experts, after the expiry of Lipitor's patent, the sale value of drug would significantly come down from the existing $12 billion annually but in terms of volume it would be one of the best attractive proposition for the generic company.

      December 24, 2009


      Share this Article!

    Back to top^